Dear Sage,
If you’re reading this post, I want to start by saying thank you for attempting to change mental health treatment. The cause is noble and the pipeline, to include Zulresso, is truly novel. The challenge with novelty is that the definition is twofold. The first definition, for which most of us are familiar, is something new or never attempted. Groundbreaking and such. This definition is the stuff that generates much excitement and fanfare.
Unfortunately, the way Zulresso is currently panning out is closer to the lesser known definition of novelty: something that is considered amusing because of its uniqueness within a somewhat culturally bound time-point. Beanie babies, Christmas villages, etc were novelty items that have been relegated to the second definition of novelty. What was once cool has become useless, cannot be sold nor given away, and sits amusingly collecting dust on a shelf. Ok, here’s where you tell me that you’re one of the “lucky ones” who had AND sold one super rare beanie baby, but I digress.
Is this the novelty we want? Zulresso is the first and only product indicated for PPD. Ok that sounds pretty cool (novel) and it works fast. Except for the darnedest aspect that this benefit of the drug is made null and void by the extreme rarity that a patient can access treatment (akin to having that ultra rare beanie). The amusing part is where we, the sales force, are being asked to just dump patients into the Sage Central vortex (enrollment forms) and (gulp) hope for the best.
Is THIS a truly novel approach to mental health?
Yours truly,
Sagean Culture-less
If you’re reading this post, I want to start by saying thank you for attempting to change mental health treatment. The cause is noble and the pipeline, to include Zulresso, is truly novel. The challenge with novelty is that the definition is twofold. The first definition, for which most of us are familiar, is something new or never attempted. Groundbreaking and such. This definition is the stuff that generates much excitement and fanfare.
Unfortunately, the way Zulresso is currently panning out is closer to the lesser known definition of novelty: something that is considered amusing because of its uniqueness within a somewhat culturally bound time-point. Beanie babies, Christmas villages, etc were novelty items that have been relegated to the second definition of novelty. What was once cool has become useless, cannot be sold nor given away, and sits amusingly collecting dust on a shelf. Ok, here’s where you tell me that you’re one of the “lucky ones” who had AND sold one super rare beanie baby, but I digress.
Is this the novelty we want? Zulresso is the first and only product indicated for PPD. Ok that sounds pretty cool (novel) and it works fast. Except for the darnedest aspect that this benefit of the drug is made null and void by the extreme rarity that a patient can access treatment (akin to having that ultra rare beanie). The amusing part is where we, the sales force, are being asked to just dump patients into the Sage Central vortex (enrollment forms) and (gulp) hope for the best.
Is THIS a truly novel approach to mental health?
Yours truly,
Sagean Culture-less